These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 14980366)

  • 1. Pathophysiology of Tourette's syndrome: striatal pathways revisited.
    Saka E; Graybiel AM
    Brain Dev; 2003 Dec; 25 Suppl 1():S15-9. PubMed ID: 14980366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does an imbalance between the dorsal and ventral striatopallidal systems play a role in Tourette's syndrome? A neuronal circuit approach.
    Groenewegen HJ; van den Heuvel OA; Cath DC; Voorn P; Veltman DJ
    Brain Dev; 2003 Dec; 25 Suppl 1():S3-S14. PubMed ID: 14980365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurology of Tourette's syndrome (TS) TS as a developmental dopamine disorder: a hypothesis.
    Nomura Y; Segawa M
    Brain Dev; 2003 Dec; 25 Suppl 1():S37-42. PubMed ID: 14980371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focused motor stereotypies do not require enhanced activation of neurons in striosomes.
    Glickstein SB; Schmauss C
    J Comp Neurol; 2004 Feb; 469(2):227-38. PubMed ID: 14694536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neural circuits that generate tics in Tourette's syndrome.
    Wang Z; Maia TV; Marsh R; Colibazzi T; Gerber A; Peterson BS
    Am J Psychiatry; 2011 Dec; 168(12):1326-37. PubMed ID: 21955933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal ganglia dysfunction in Tourette's syndrome: a new hypothesis.
    Mink JW
    Pediatr Neurol; 2001 Sep; 25(3):190-8. PubMed ID: 11587872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Ningdong granule on the dopamine system of Tourette's syndrome rat models.
    Lv H; Li A; Ma H; Liu F; Xu H
    J Ethnopharmacol; 2009 Jul; 124(3):488-92. PubMed ID: 19467315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurophysiology of Tourette's syndrome: pathophysiological considerations.
    Segawa M
    Brain Dev; 2003 Dec; 25 Suppl 1():S62-9. PubMed ID: 14980375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine and the diseased brain.
    Kienast T; Heinz A
    CNS Neurol Disord Drug Targets; 2006 Feb; 5(1):109-31. PubMed ID: 16613557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
    Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurobiology of Tourette's syndrome: concepts of neuroanatomic localization and neurochemical abnormalities.
    Singer HS; Minzer K
    Brain Dev; 2003 Dec; 25 Suppl 1():S70-84. PubMed ID: 14980376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gamma-aminobutyric acidA and benzodiazepine receptor alterations in the rat brain after unilateral 6-hydroxydopamine lesions of the medial forebrain bundle.
    Araki T; Matsubara M; Fujihara K; Kato H; Imai Y; Itoyama Y
    Neurol Res; 2002 Jan; 24(1):107-12. PubMed ID: 11783749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET.
    Singer HS; Szymanski S; Giuliano J; Yokoi F; Dogan AS; Brasic JR; Zhou Y; Grace AA; Wong DF
    Am J Psychiatry; 2002 Aug; 159(8):1329-36. PubMed ID: 12153825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal dopamine output is compromised within +/- BDNF mice.
    Dluzen DE; Anderson LI; McDermott JL; Kucera J; Walro JM
    Synapse; 2002 Feb; 43(2):112-7. PubMed ID: 11754489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease.
    Tillerson JL; Caudle WM; Reverón ME; Miller GW
    Neuroscience; 2003; 119(3):899-911. PubMed ID: 12809709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased plasma membrane expression of striatal dopamine transporter in aging.
    Salvatore MF; Apparsundaram S; Gerhardt GA
    Neurobiol Aging; 2003 Dec; 24(8):1147-54. PubMed ID: 14643386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of GAP-43 protein and mRNA in nigrostriatal dopaminergic neurons after the partial destruction of dopaminergic terminals with intrastriatal 6-hydroxydopamine.
    Iwata SI; Nomoto M; Fukuda T
    Synapse; 2001 Jan; 39(1):16-22. PubMed ID: 11071705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
    Betarbet R; Greenamyre JT
    Exp Neurol; 2004 Oct; 189(2):393-403. PubMed ID: 15380489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and cellular alterations in the Pitx3-deficient midbrain dopaminergic system.
    Smits SM; Mathon DS; Burbach JP; Ramakers GM; Smidt MP
    Mol Cell Neurosci; 2005 Nov; 30(3):352-63. PubMed ID: 16140547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGF-2 and S100beta immunoreactivities increase in reactive astrocytes, but not in microglia, in ascending dopamine pathways following a striatal 6-OHDA-induced partial lesion of the nigrostriatal system.
    Chadi G; Gomide VC
    Cell Biol Int; 2004; 28(12):849-61. PubMed ID: 15566955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.